Sana Biotechnology Inc (SANA) concluded trading on Wednesday at a closing price of $3.50, with 14.27 million shares of worth about $49.96 million changed hands on the day. Half year performance of the stock remained negative as price took a plunge of -42.72% during that period and on January 22, 2025 the price saw a gain of about 19.86%. Currently the company’s common shares owned by public are about 223.11M shares, out of which, 122.70M shares are available for trading.
Stock saw a price change of -3.58% in past 5 days and over the past one month there was a price change of 107.72%. Year-to-date (YTD), SANA shares are showing a performance of 114.72% which decreased to -30.83% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $1.52 but also hit the highest price of $12.00 during that period. The average intraday trading volume for Sana Biotechnology Inc shares is 6.11 million. The stock is currently trading 39.78% above its 20-day simple moving average (SMA20), while that difference is up 42.03% for SMA50 and it goes to -32.10% lower than SMA200.
Sana Biotechnology Inc (NASDAQ: SANA) currently have 223.11M outstanding shares and institutions hold larger chunk of about 53.35% of that.
The stock has a current market capitalization of $781.45M and its 3Y-monthly beta is at 1.58. It has posted earnings per share of -$1.41 in the same period. It has Quick Ratio of 4.47 while making debt-to-equity ratio of 0.33. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for SANA, volatility over the week remained 19.19% while standing at 17.96% over the month.
Analysts are in expectations that Sana Biotechnology Inc (SANA) stock would likely to be making an EPS of -0.26 in the current quarter, while forecast for next quarter EPS is 0 and it is -0.97 for next year. For the current quarter EPS, analysts have given the company a lowest target -0.31 which is -0.22 at the higher side of the target for the same. When we compare those targets with actual EPS, we find that company posted an EPS of -0.35 in the same quarter a year ago. Stock’s fiscal year EPS is expected to rise by 17.68% while it is estimated to increase by 27.22% in next year.
On June 26, 2024, Rodman & Renshaw Initiated their recommendations, while on January 16, 2024, H.C. Wainwright Upgrade their ratings for the stock with a price target of $12. Stock get a Mkt outperform rating from JMP Securities on September 25, 2023.
